Lionco Pharmaceutical Group Co.,Ltd.

603669

CNE1000022R8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
4.72 ^CNY	+0.85%		-1.46%	-14.65%

04-19	Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01-31	Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	CI

Lionco Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.

March 07, 2022

The Board of Directors of Lionco Pharmaceutical Group Co.,Ltd. has authorized a buyback plan on March 8, 2022.

Latest news about Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	01-30	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on January 31, 2023, has closed with 8,785,900 shares, representing 1.22% for CNY 50 million.	01-27	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	01-02	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on January 31, 2023.	11-13	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-20	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Lionco Pharma Registers Latamoxef Sodium for Injection in China	23-08-04	MT
Lionco Pharma's Bacterial Drug Passes Regulator's Evaluation	23-06-21	MT
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
Lionco Pharma Unit's Aztreonam for Injection Passes Drug Regulator's Evaluation	23-04-18	MT
Lionco Pharma to Raise Up to 100 Million Yuan Through Share Buyback	23-01-31	MT
Lionco Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	23-01-30	CI
Lionco Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	23-01-28	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	23-01-10	CI
Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback announced on March 10, 2022 has closed with 8,915,893 shares, for CNY 60 million.	23-01-08	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	23-01-05	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	22-10-10	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Tranche Update on Lionco Pharmaceutical Group Co.,Ltd.'s Equity Buyback Plan announced on March 10, 2022.	22-07-04	CI
Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI

Chart Lionco Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Lionco Pharmaceutical Group Co.,Ltd.

More charts

Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.

Sector

Pharmaceuticals

Calendar

2024-07-12 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LIONCO PHARMACEUTICAL GROUP CO.,LTD.	-14.65%	457M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.77B
OTSUKA HOLDINGS CO., LTD.	+28.00%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+18.82%	14.34B
ZYDUS LIFESCIENCES LIMITED	+55.83%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.70%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B